The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2
- 1 February 1991
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 63 (2) , 275-278
- https://doi.org/10.1038/bjc.1991.64
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Immunologic study of human recombinant interleukin-2 (low dose) in patients with advanced renal cell carcinomaUrology, 1989
- The international standard for human interleukin-2Journal of Immunological Methods, 1988
- Metastatic Renal Cancer Treated with Interleukin-2 and Lymphokine-Activated Killer CellsAnnals of Internal Medicine, 1988
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Recombinant interleukin-2 directly augments the cytotoxicity of human monocytesNature, 1987
- Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2.The Journal of Immunology, 1986
- Characterization of human interleukin 2 derived from Escherichia coliBiochemical Journal, 1985
- Reporting results of cancer treatmentCancer, 1981
- T Cell Growth Factor: Parameters of Production and a Quantitative Microassay for ActivityThe Journal of Immunology, 1978